{"transactions":[{"id":3195356,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2020-03-25T17:28:54.000Z","date":"2020-03-23","kind":"sale","acquired":false,"shares":50358,"price":2.1741,"value":109483.3278,"ownership":{"direct":false,"nature":"By corporation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.16 to $2.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities reported are held directly by Clal Biotechnology Industries Ltd. (\"CBI\"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. (\"CI\") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose."}],"balance_after":940590,"source":{"system":"sec-edgar","filing":"0001209191-20-021160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919120021160/doc4.xml","form_type":"4"}},{"id":3195355,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2020-03-25T17:28:54.000Z","date":"2020-03-24","kind":"sale","acquired":false,"shares":84286,"price":2.1923,"value":184780.1978,"ownership":{"direct":false,"nature":"By corporation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.19 to $2.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities reported are held directly by Clal Biotechnology Industries Ltd. (\"CBI\"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. (\"CI\") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose."}],"balance_after":856304,"source":{"system":"sec-edgar","filing":"0001209191-20-021160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919120021160/doc4.xml","form_type":"4"}},{"id":3195354,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2020-03-25T17:28:54.000Z","date":"2020-03-24","kind":"sale","acquired":false,"shares":117400,"price":2.2022,"value":258538.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":1896176,"source":{"system":"sec-edgar","filing":"0001209191-20-021160","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919120021160/doc4.xml","form_type":"4"}},{"id":3198010,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2020-03-23T21:00:18.000Z","date":"2020-03-19","kind":"sale","acquired":false,"shares":9050,"price":2.5149,"value":22759.845,"ownership":{"direct":false,"nature":"By corporation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.49 to $2.57, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities reported are held directly by Clal Biotechnology Industries Ltd. (\"CBI\"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. (\"CI\") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose."}],"balance_after":990948,"source":{"system":"sec-edgar","filing":"0001209191-20-020788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919120020788/doc4.xml","form_type":"4"}},{"id":3198009,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2020-03-23T21:00:18.000Z","date":"2020-03-20","kind":"sale","acquired":false,"shares":84339,"price":2.2161,"value":186903.6579,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.21 to $2.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":2013576,"source":{"system":"sec-edgar","filing":"0001209191-20-020788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919120020788/doc4.xml","form_type":"4"}},{"id":3875561,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"exercise","acquired":false,"shares":3914590,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":782917},"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}},{"id":3875560,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Series A Preferred Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"exercise","acquired":false,"shares":5000000,"ownership":{"direct":false,"nature":"By corporation"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported are held directly by Clal Biotechnology Industries Ltd. (\"CBI\"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. (\"CI\") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":999998},"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}},{"id":3875559,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Series A Preferred Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"exercise","acquired":false,"shares":5000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":999998},"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}},{"id":3875558,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"purchase","acquired":true,"shares":315000,"price":16,"value":5040000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":2097915,"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}},{"id":3875557,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"exercise","acquired":true,"shares":782917,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects conversion of shares of Series B Preferred Stock into shares of Common Stock in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series B Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH received $16.00 for the cash settlement of an aggregate of 1 fractional share of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":1782915,"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}},{"id":3875556,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"exercise","acquired":true,"shares":999998,"ownership":{"direct":false,"nature":"By corporation"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported are held directly by Clal Biotechnology Industries Ltd. (\"CBI\"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. (\"CI\") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose."}],"balance_after":999998,"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}},{"id":3875555,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":46924,"kind":"organization","name":"Access Industries Holdings LLC","position":1,"cik":"0001391297","reported_name":"Access Industries Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131387,"kind":"organization","name":"Clal Biotechnology Industries Ltd.","position":2,"cik":"0001468950","reported_name":"Clal Biotechnology Industries Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":51978,"kind":"organization","name":"ACCESS INDUSTRIES, LLC","position":3,"cik":"0001508227","reported_name":"ACCESS INDUSTRIES, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46925,"kind":"organization","name":"ACCESS INDUSTRIES MANAGEMENT, LLC","position":4,"cik":"0001508226","reported_name":"ACCESS INDUSTRIES MANAGEMENT, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":46929,"kind":"person","name":"Blavatnik Len","position":5,"cik":"0001326628","reported_name":"Blavatnik Len","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2018-07-03T14:10:19.000Z","date":"2018-06-29","kind":"exercise","acquired":true,"shares":999998,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects conversion of shares of Series A Preferred Stock into shares of the Issuer's common stock, $0.001 par value per share (\"Common Stock\"), in connection with the closing of the Issuer's initial public offering of Common Stock on approximately a 5:1 basis exempted under Rule 16b-6(b). The Series A Preferred Stock were convertible at any time into shares of Common Stock and had no expiration date. In connection with the conversion, fractional shares of Common Stock were cash settled at a value of $16.00 per share. AIH and CBI (each as defined below) each received $32.00 for the cash settlement of an aggregate of 2 fractional shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Access Industries Holdings LLC (\"AIH\") and may be deemed to be beneficially owned by Access Industries, LLC (\"Access LLC\"), Access Industries Management, LLC (\"Management LLC\") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose."}],"balance_after":999998,"source":{"system":"sec-edgar","filing":"0001209191-18-040738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000120919118040738/doc4.xml","form_type":"4"}}]}